预约演示
Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology
临床2期临床1期免疫疗法并购高管变更
Biogen plans to use its rare disease capabilities to develop and commercialize anti-CD38 antibody felzartamab.
Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification visanti-CD38 antibodyafelzartamabecured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.
Biogencher identified Biogen’s focus on neuroscience as a problem after he took over as CEO of the Big Biotech. For Biogenany of its sizeHuman Immunology BiosciencescuHI-Bioiehbacher reckoned, and that was particularlyanti-CD38 monoclonal antibodyline skewed toward high-risk neuroscience programs. The CEO responded to the perceived problem by outlining plans to expand in other areas, notably immunology.
That plan took off WedBiogen, when Biogen disclosed a deal to buy HI-Bio for $1.15 billion upfront Big Biotech650 million in potential mileBiogenpayments. The deal will give Biogen control of the anti-CD38 antibody felzartamab.
“We believe this late-stage asset, Biogenhas demonstrated impact oHI-Biobiomarkers and clinical endpoints in three renal diseases with serious unmet needs, is a strategic addBiogento the Biogen poanti-CD38 antibodyifelzartamabent our pipeline and build on our expertise in immunology,” Priya Singhal, M.D., head of development at Biogen, said in a statement.
HI-Bio identified the ability of felzartamab to selectively deplete CD38-positive cells as a way to treat a range orenal diseasested diseases. The biotech has phase 2 data in primary membBiogen nephropathy (PMN) and antibody-mediated rejection (AMR). A midstage study in IgA nephropathy (IgAN) is ongoing.Biogen
HI-Biootech plans to run phase 3 felzartamabMR, PMN and IgAN. The breadth of the program, coupled to the potential toimmune-mediated diseasesiated diseases such as lupus, giveprimary membranous nephropathy (PMN)ntly antibody-mediated rejection (AMR) through a single pipeIgA nephropathy (IgAN)vided the molecule succeeds in the clinic.
Biogen plans to use its rare disease capabilities to devIgAN and commercialize the antibody. The goal is to retain expertise and taimmune-mediated diseasesbased HI-lupusnd estabBiogen Bay Area team focused on immune-mediated diseases. In addition to felzartamab, Biogen is acquiring a phase 1 anti-C5aR1 antibody with applications in complement-mediated diseases as part of the takeover.
Biogentamab has taken a circuitous route to this point. MorphoSys developed the antibody as a would-be rival to Johnson & Johnson and Genmab’s multiple myeloma dHI-Biorzalex. Celgene struck a deal for the asseimmune-mediated diseasesway less than twofelzartamabr.Biogeno licensed the antibody anti-C5aR1 antibody 2022.complement-mediated diseases
Felzartamabook HI-Bio equity as part of the deal, endingMorphoSysr with a 12% stake in the firm. Novartis, whichJohnson & Johnson buy GenmabSysmultiple myelomaeneficDarzalexthCelgeneof the stake.HI-Bio
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。